game two halv
cover
pharmaceut sector alistair year experi previous cover
european biotechnolog cazenov european continent pharmaceut citigroup
pan-european pharmaceut jpmorgan alistair hold degre biochemistri
univers oxford qualifi manag account glaxo
alistair work sever healthcar ipo includ oxford glycosci weston
medic grifol ablynx
laura sutcliff join berenberg prior spent four year strategi
consult work healthcar bank client hold phd engin
mphil bioscienc enterpris ba zoolog univers cambridg
david hogg year experi cash equiti start career
analyst five year move specialist sale prior join berenberg
previous work dresdner kleinwort commerzbank bear stearn mf
disclosur respect section german secur trade act
wertpapierhandelsgesetz wphg disclaim pleas see end
pleas note use research report subject condit restrict
set forth disclosur disclaim end document
tabl content
game two halv
abbvi inc invest thesi pictur
invest point one greater clariti humira emerg
invest point two import growth driver haematolog
final reckon futur secur price
game two halv
fire cylind huge challeng ahead initi
hold recommend thrive sinc separ
abbott larg part on-going success
autoimmun drug humira grew sale
howev humira near end exclus
biosimilar arriv europ year us
compani also assembl impress list new growth driver
oncolog auto-immun result outpac
peer term sale earn growth next five year
howev think growth come abrupt end
compani may endur sever year declin thereaft dcf
captur cash flow outlook inflect suggest fair
valu set price target initi
humira twilight year humira remark success abbott/
acquir still phase develop
humira gener sale world largest
drug howev approach loss exclus biosimilar
launch europ octob year us forecast
sale peak swiftli declin thereaft
new launch drive sector beat near term growth oncolog drug
imbruvica venclexta chang standard care chronic
lymphocyt leukaemia cll expand area
autoimmun drug risankizumab upadacitinib come
market next year endometriosi drug elagolix gain
approv year-end expect five product deliv
increment sale lead compound sale growth
compound earn growth
fortun like turn new launch still grow
beyond unlik abl off-set demis humira post-
result think compani slip earn declin
possibl multi-year period captur turnaround valuat
challeng given move part nevertheless long-rang dcf
suggest fair valu
initi hold despit impress line-up growth
product think current portfolio abl off-set
demis humira trade discount us peer
earn think discount warrant dcf-deriv price
target equat discount peer
none hold
perform rel
us-bas biopharmaceut
compani discov manufactur
sell pharmaceut product
inflammatori
focu
profit loss summari
growth margin
set strong growth five-year view thank good
sale momentum recent launch imbruvica venclexta
high-potenti pipelin project set come market
forecast sale grow earn pa
substanti ahead sector
howev mark turn fortun compani
humira largest drug face biosimilar competit us
forecast us sale erod pa
thereaft expect face sever year declin
earn make valu compani particularli
dcf model best captur long-term prospect
suggest fair valu set price target accordingli
equival peak earn seem realist
given potenti earn declin thereaft
chang net debt
average cost debt
risk invest thesi
downsid signific setback phase pipelin eg
safeti issu upadacitinib would erod near-term growth
addit although settl biosimilar entrant
us litig on-going other could result
competit earlier anticip
upsid posit data pipelin could lead rais
expect sever product eg good data upadacitinib
may also seek addit in-licens opportun
bolster pipelin could eas sale earn pressur
middl next decad
abbvi inc invest thesi pictur
chart today highli depend humira
chart biosimilar competit come
sale product
sale product
sale product
sale product
samsung bioepi partner
eu merck us
phase psoriasi
chart assembl impress new portfolio
chart sale grow high singl digit
chart margin expect approach
chart beyond expect revers fortun
sale ebit index
sale ebit index
sale ebit index
sale ebit index
new initi coverag us pharmaceut compani hold
recommend set price target offer upsid current level
two-minut summari compani fascin time develop lead
product humira world largest drug repres sale howev
face biosimilar competit europ year us becom
major headwind meanwhil compani assembl impress list new
product includ two market drug blood cancer three excit late-stag
product auto-immun diseas women health mean growth prospect
near term excel forecast sale grow pa
earn pa significantli ahead peer howev mark abrupt
turnaround fortun busi like slip declin unless
deliv pipelin
price investor pay outlook share trade discount
us peer group earn market clearli awar challeng ahead
forecast trade peak ep inde mark
swing growth declin earn single-digit multipl warrant
view dcf cover cash flow forecast suggest fair valu set
price target impli de-rat earn earn inflect
point initi hold recommend
invest point one humira problem
pharmaceut divis enjoy tremend
success autoimmun drug humira acquir part transact
abbott creat lead product autoimmun diseas eg
rheumatoid arthriti psoriasi gener sale make
world largest drug repres group sale howev good thing come
end humira approach final stage patent protect life biosimilar
expect launch europ octob year reach settlement
agreement samsung result biosimilar launch
us latest
humira sale like stagnat level slip
signific declin thu strongest growth driver last year enter
twilight year becom seriou sale headwind middl next decad
abbvi face major transit humira new product portfolio
invest point two import growth driver hematolog
paid acquir biotechnolog compani pharmacycl gave
joint ownership btk inhibitor imbruvica global profit imbruvica
split equal johnson johnson recognis us
sale profit share ex-u sale revenu line imbruvica transform
treatment cll use signific proport first-lin patient
mani patient advanc diseas forecast peak sale
includ risk-adjust estim potenti new indic follicular
venclexta inhibitor also approv cll intern drug
develop although compani chose partner roch clinic
develop commercialis given roch expertis diseas area like
imbruvica data thu far extrem impress fact physician talk
particularli excit deep remiss mani patient achiev
venclexta think becom standard care cll acut myeloid leukaemia
aml also clinic develop multipl myeloma forecast risk-adjust
peak sale
combin imbruvica venclexta add sale
anticip humira declin invest heavili pipelin intern
project in-licens deal three product late-stag develop look particularli
abbott in-licens gonadotrophin releas hormon antagonist elagolix
develop endometriosi uterin fibroid phase
data endometriosi strong drug file approv
process suffer small delay regul respond safeti observ
compet project data elagolix look clean expect formal us approv
second half year product
paid boehring ingelheim co-develop two auto-immun
project import antibodi risankizumab
risankizumab lead indic psoriasi shown competit efficaci
profil nevertheless late arriv market also develop
inflammatori bowel diseas crohn could signific indic
forecast risk-weight peak sale
final develop jak inhibitor call upadacitinib complet phase
develop thu far data strong reach market
first drug class pfizer xeljanz lilli olumi alreadi approv may
cleaner profil due specif main indic rheumatoid
arthriti alreadi enjoy strong posit humira ahead
indic atop dermat could interest forecast risk-adjust peak
sale
invest point four game two halv
footbal term true game two halv
forecast sector lead sale earn growth despit ex-u biosimilar competit
humira deliv least stabl revenu allow increment growth five
major growth product drive compound sale growth comfort
ahead sector addit combin fall payaway humira
oper leverag busi expect drive ebit margin around
result forecast compound non-gaap ep growth
nearli twice growth rate expect wider pharmaceut sector
howev compani precari posit accord forecast
humira still repres around sale like swift retreat lose
volum net price extrem challeng headwind face
includ risk-weight sale earli stage pipelin forecast sale fall
pa furthermor non-gaap ebit margin larg part
thank domin one larg drug real payaway contrast
new growth driver eg imbruvica venclexta risankizumab elagolix
carri profit share royalti payment thu expect ebit margin
last see ebit retreat faster sale
sale ebit strong growth revers thereaft
sale ebit index
sale ebit index
sale ebit index
sale ebit index
result mix outlook think abbvi discount us sector
pe broadli warrant dcf model adequ captur long-term
cash flow trajectori point fair valu upsid current level
nevertheless given signific uncertainti model initi coverag
hold rate price target
broadli line consensu sale non-gaap earn howev
differ significantli three key product area
consensu hepat portfolio keep
hepat market model expect gilead
contrast venclexta forecast significantli ahead consensu much
believ venclexta standard care cll
segment aml feedback physician extrem posit
also optimist outlook risankizumab forecast
sit consensu howev significantli lower
abbvi nomin sale ambit
summari differ consensu product basi think
major differ group level
group level sale non-gaap earn forecast rel close align
consensu howev differ consensu notabl sever abbvi
close consensu hepat sale year expect market
show steadi declin number treat patient year fall align
gilead hepat forecast consensu expect
consider optimist consensu venclexta sale discuss
confid drug cll aml previou section
nearli ahead consensu
risankizumab forecast despit nomin sale project
ahead consensu
medium-term outlook driven quit larg move part
make forecast challeng beyond think two biggest uncertainti
eros profil humira impact margin
abbvi abil achiev full sale potenti pipelin particularli cancer
drug imbruvica venclexta
doomsday scenario swift adopt humira biosimilar
doomsday scenario swift adopt humira biosimilar
doomsday scenario swift adopt humira biosimilar
doomsday scenario swift adopt humira biosimilar
assum believ fair eros rate humira post-biosimilar
entri around pa howev given size product thu extent
save could achiev envis scenario product erod
assum eros rate pa five-year window follow us biosimilar
also assum neg bp impact long-term margin result faster
scenario dcf drop neg impact valuat
blueblueblueblu -- -- sky scenario imbruvica venclexta fulfil potenti
sky scenario imbruvica venclexta fulfil potenti
sky scenario imbruvica venclexta fulfil potenti
sky scenario imbruvica venclexta fulfil potenti
discuss bodi note imbruvica venclexta two class-lead anti-
cancer drug deliv excel efficaci cll drug develop
haematolog cancer could signific sale potenti outsid cll eg
imbruvica fl venclexta multipl myeloma
model scenario imbruvica venclexta approach nomin
sale expect ie risk-adjust
assum venclexta reach global sale peak
imbruvica reach sale recognis peak
margin benefit boost given expect profit special cancer
drug magnitud sale
scenario dcf increas posit impact valuat
invest point one greater clariti humira
humira lead anti-inflammatori drug gener sale
world best sell medicin howev drug approv
us approach end patent life biosimilar expect
launch europ year recent settlement samsung
bioepi mean biosimilar competit us like earli
humira domin busi today group sale rate
eros medium term critic group outlook outsid us expect
humira sale declin pa assum sale us
erod pa beyond biosimilar competit well
expect global sale reach grow low singl digit
peak thereaft model declin franchis drop
world biggest drug
abbvi humira anti-tnf antibodi approv wide rang auto-immun
condit gener sale world best-sel medicin
howev drug approach end patent life biosimilar competit
way
europ biosimilar expect launch year humira sale start
erod meaning onward exampl biosimilar entri european
sale drop yoy although rate drop vari significantli
countri guid annual eros around
seem optimist may justifi fact humira still grow versu enbrel
remicad alreadi declin biosimilar competit enter market
howev despit competit loom europ sale us make least two-
third total biosimilar competit may significantli delay
built comprehens suit intellectu properti includ patent
provid protect next decad
recent sign settlement agreement sever biosimilar compani
greatli clarifi time entri europ us
settlement biosimilar humira date
samsung bioepi partner
eu merck us
thu far three biosimilar challeng settl abbvi sandoz
coheru boehring ingelheim
clear biosimilar launch europ year look
less like biosimilar launch us provid
four- five-year window bring pipelin market establish next wave
product
expect global humira sale peak year
last year humira avoid biosimilar competit major
year repres peak humira sale model
onward expect gradual acceler declin sale outsid us
forecast sale drop acceler
us expect humira growth moder simpli due size product
model true biosimilar eros onward still earli get
good idea us biosimilar eros curv tend believ system get
comfort biosimilar pressur build rein cost time
biosimilar eros curv steepen
overal expect humira deliv global sale sale
grow modestli peak beyond model substanti
declin driven fall us sale
haematolog
built impress oncolog franchis initi focu
haematolog cancer chronic lymphocyt leukaemia cll first drug
market imbruvica first-in-class bruton tyrosin kinas btk inhibitor
estim us peak sale recent launch first class
inhibitor venclexta estim risk-adjust peak sale us
imbruvica launch extrem well cll three phase trial deliv
extrem strong improv progression-fre surviv
first-lin cll elderli patient imbruvica dramat extend compar
chlorambucil hazard ratio reson patient
relaps cll imbruvica deliv impress benefit versu arzerra
hazard ratio helio studi also relaps cll show imbruvica
ad bendamustine/rituxan br versu br alon deliv robust
improv hazard ratio
forecast peak imbruvica sale us book sale
peak ex-u profit share incom risk-adjust forecast
sale potenti could higher particularli imbruvica show good efficaci
b-cell malign follicular lymphoma forecast line
consensu
venclexta recent launch first indic relaps cll patient
specif genet mutat del recent label expand includ
cll patient receiv least one prior therapi base
murano trial show venclexta plu rituxan deliv major
prolong compar br hazard ratio venclexta broad
develop programm see move first line also
diseas area aml multipl myeloma
peak us sale risk-adjust potenti reach
higher success futur trial venclexta develop collabor
roch pay royalti us sale profit share ex-u sale
imbruvica first-in-class btk inhibitor approv rang cell
malign cll major indic class drug
clinic data cll outstand reson
trial show impress improv second-lin first-lin diseas
hazard ratio respect
unlik mani treatment cll btk inhibitor need taken continu
diseas progress mean durat treatment much longer
drug space may caus problem imbruvica associ
increas risk seriou bleed increas incid atrial fibril
target btk inhibitor come market eg astrazeneca calquenc data
expect phase head-to-head trial calquenc versu imbruvica
relaps cll provid much better insight competit
risk pose drug
nevertheless imbruvica launch strongli compel efficaci data
room expand diseas area forecast risk-weight peak sale
us alon forecast broadli line guidanc consensu
imbruvica ibrutinib btk inhibitor approv treatment varieti b-cell
malign potenti indic come includ solid tumour ie
pancreat cancer compound initi discov biopharmaceut compani
pharmacycl compani enter world-wide profit-shar
agreement drug decemb drug first approv us
novemb treatment mantl cell lymphoma patient receiv
least one prior therapi acquir pharmacycl may
valuat drew sceptic among investor larg driven high expect
revenu imbruvica book us revenu book revenu rest
world
inappropri activ b-cell receptor key driver cancer cell surviv
prolifer rang b-cell lymphoma result intens
research focu develop inhibitor downstream kinas pathway
spleen tyrosin kinas btk phosphoinositid imbruvica
first btk gain approv shown remark efficaci rang b-cell
sinc initi approv second-lin treatment mantl cell lymphoma
imbruvica achiev approv small lymphocyt lymphoma sll cll margin
zone lymphoma mz waldenstrom macroglobulinemia wm chronic graft-versus-
host diseas cgvhd continu gain popular move treatment
paradigm accord nation comprehens cancer network nccn guidelin
largest patient popul cll/sll imbruvica rank second popular
agent first-lin treatment prefer therapi second-lin diseas high-
risk cll patient mutat imbruvica prefer treatment
method first second line
imbruvica plethora indic continu expand come year
hope pick approv haematolog cancer well metastat
imbruvica fda approv timelin actual expect indic therapi stage
cll/sll metastat pancreat cancer largest commerci opportun base
patient popul see chart although pancreat cancer non-b-cel cancer
higher risk proposit mechan action
estim incid imbruvica target indic us
btk inhibitor work -- -- cell malign cur
btk inhibitor work
cell malign cur
btk inhibitor work
btk inhibitor work
cell malign cur
cell malign cur
b-cell lymphoma leukaemia deriv b-cell infect fight cell
immun system found lymph node spleen thymu bone marrow
normal cours affair cell respond infect produc antibodi
infect agent howev cell mutat begin prolifer
uncontrol way
often defect b-cell receptor bcr signal pathway central
develop b-cell cancer btk central bcr signal function thu
essenti develop matur cell therefor play
import role pathogenesi cell lymphoma
imbruvica small molecul irrevers inhibitor btk highli effect
stop b-cell prolifer surviv
imbruvica highli effect medicin cll deliv impress progress
free surviv result cll second-lin set reson first-lin
reson trial imbruvica test antibodi arzerra
patient fail least one line therapi higher risk eg coexist
condit imbruvica deliv impress improv versu arzerra
hazard ratio
imbruvica versu arzerra ofatumumab r/r cll impress
test imbruvica versu chemotherapeut agent chlorambucil
patient newli diagnos cll older coexist morbid
would preclud use fcr fludarabin cyclophosphamid rituximab
imbruvica deliv impress improv median
reach data publish
imbruvica versu chlorambucil front-lin cll impress
chronic treatment requir side -- -- effect mount
chronic treatment requir side
chronic treatment requir side
chronic treatment requir side
although imbruvica clearli highli effect keep diseas control
drive deep respons reson imbruvica show partial respons rate
complet respons earlier-stag patient respons rate
complet respons rate given imbruvica erad
diseas given fast deterior sometim seen patient come
imbruvica therapi patient gener recommend stay imbruvica
progress death caus problem patient imbruvica
trigger atrial fibril seriou bleed small number patient eg atrial
fibril median follow month increas
better btk inhibitor come market
better btk inhibitor come market
better btk inhibitor come market
better btk inhibitor come market
imbruvica rel unselect kinas inhibitor inhibitori activ
number tyrosin kinas activ non-btk kinas thought explain
imbruvica side-effect compani develop select btk inhibitor
safer clinic profil eg astrazeneca/acerta acalabrutinib kinom
acalabrutinib ibrutinib show much target acalabrutinib
american societi haematolog
astrazeneca acalabrutinib gain acceler approv us treat second-lin
mantl cell lymphoma brand name calquenc compar mantl cell
lymphoma mcl data calquenc imbruvica show good overal respons rate
drug perhap suggest respons calquenc higher
proport complet respons safeti incid side-effect gener
lower calquenc compar imbruvica except headach
look much higher calquenc
imbruvica versu calquenc mcl
median time dx mth
imbruvica calquenc prescrib inform
rel profil imbruvica calquenc close defin
astrazeneca head-to-head trial elevate-rr studi pitch calquenc
imbruvica previous treat cll data expect primari end-
point secondari end-point focus safeti eg infect risk incid
atrial fibril physician talk expect see signific
differ efficaci possibl differ safeti profil think
elevate-rr result dramat switch calquenc clear differ safeti
help calquenc gain share time
solid tumour high risk big opportun
high risk big opportun
high risk big opportun
high risk big opportun
test imbruvica pancreat cancer evid suggest
btk inhibitor could slow diseas progress mast cell play import role
pancreat cancer angiogenesi growth releas pro-angiogen
tissu degrad mediat mean presenc posit correl
tumour progress mous human model pancreat cancer
shown inhibit btk also inhibit mast cell migrat function theori
lead depress tumour growth howev ibrutinib suffer multipl off-
target effect inhibit itk txk import effector
t-cell function therefor immune-medi anti-tumour activ could limit
ibrutinib efficaci solid tumour
abbvi phase ii/iii resolv trial investig ibrutinib combin nab-
paclitaxel gemcitabin versu placebo first-lin treatment metastat
pancreat adenocarcinoma due complet march result trial
indic whether ibrutinib could legitim therapi pancreat cancer
howev low expect data present studi ibrutinib plu
durvalumab patient relapsed/refractori solid tumour show limit activ
overal respons rate breast cancer pancreat cancer
ition altern mechan action
competit
altern mechan action
ition
ition
altern mechan action
altern mechan action
abbvi main competit come astrazeneca acalabrutinib
line btk inhibitor develop beigen zanubrutinib
competitor btk inhibitor advanc term develop claim lower
off-target activ discuss acalabrutinib calquenc alreadi approv
treatment relapsed/refractori mcl soon approv cll wherea
zanubrutinib like come market end
primari complet upcom trial
btk inhibitor approv develop
area focu
area focu
area focu
area focu
tabl give complet list btk inhibitor current approv
develop phase area focu compani either pursu oncolog
indic would compet imbruvica prioritis autoimmun
condit rheumatoid arthriti multipl sclerosi compani appear
equal commit area suspect due differ price paramet
btk inhibitor test oncolog beyond calquenc expect much
differenti except arqul sunesi compound may
differ efficaci safeti due non-coval mode action may
necessarili compet directli like imbruvica could use follow-on
btki patient becom resist initi therapi btk inhibitor form
inhibitor inhibitor impact btk use
inhibitor inhibitor impact btk use
inhibitor inhibitor impact btk use
inhibitor inhibitor impact btk use
imbruvica transform treatment cll sinc approv indic
howev two drug class signific efficaci cll also emerg
could challeng futur btk inhibitor
discuss inhibitor next section good news
lead drug class competitor close market
result inhibitor turn success class benefit even
expens btk use
new class drug emerg field inhibit pathway
zydelig inhibitor approv relaps cll combin
rituxan cll trial show ad zydelig rituxan deliv impress
extens hazard ratio howev came expens sever
toxic label black box warn fatal and/or seriou hepatotox
diarrhoea pneumon intestin perfor
due toxic stage consid reserv advanced-stag patient
like alreadi fail btk inhibit
lot inhibitor test clinic two approv use
note target class four variant alpha beta gamma delta two
approv drug zydelig aliqopa target inhibitor block one
larg develop inhibitor discontinu due excess
think target inhibitor like come market time
think gener toxic seen agent mean see much use
ahead btk inhibitor given rel toxic profil
inhibitor approv develop focu oncolog
accord around sale imbruvica come cll set
given excel efficaci potenti long durat use broadli agre
around risk-adjust us sale forecast come indic result
focus assumpt set cll assum follow
first-lin patient receiv btk inhibitor repres
aggress diseas cours eg associ diseas older patient unlik
toler fcr progress second-lin therapi receiv btk
first-lin assum patient prescrib btk inhibitor
although market becom increasingli competit time assum
imbruvica retain domin posit share btk market
one difficult aspect forecast judg durat therapi
median reson reach yet btk
arm assum averag durat therapi year second-lin diseas
three year first-lin set could signific underestim
assum discount list price minim price increas us beyond
given excel data thu far label us appli risk-
adjust cll sale
assumpt result peak cll/sll sale forecast us alon
imbruvica us sale forecast indic
cll total
indic either label develop signific sale could come
mcl follicular lymphoma pancreat cancer multipl myeloma three
indic heavili risk-adjust model could major sourc
sale upsid posit data emerg clinic trial
pancreat cancer could major commerci opportun indic
explor biolog pancreat cancer suggest btk inhibitor
could knock mast cell activ thought promot tumour growth
howev data thu far ibrutinib shown poor respons rate pancreat
cancer assum chanc success
multipl myeloma anoth potenti larg indic howev expert
spoken hope cite lack cell receptor activ tumour
assum probabl success
btk
lymphoma
underwhelm sign activ rel low respons rate compar
potenti option expert excit area btk
inhibitor assum chanc success
differ consensu
differ consensu
differ consensu
differ consensu
believ imbruvica deliv risk-adjust peak sale excess
given relationship book us sale
plu profit share ex-u revenu forecast
peak close align guidanc
consensu estim bloomberg indic market expect ibrutinib
gener revenu thu also close align
risks/wher could wrong
risks/wher could wrong
risks/wher could wrong
risks/wher could wrong
think two possibl area forecast imbruvica could prove
durat therapi patient need stay btk therapi long possibl
model drug oncolog typic assum averag durat
therapi close observ median result trial imbruvica data
major phase trial cll yet reach median thu
estim durat therapi assumpt may well prove
conserv month depend line therapi
futur indic shown tabl heavili risk-adjust
futur indic eg pancreat cancer multipl myeloma caution
base disappoint earli data trial could surpris upsid
venclexta new standard care cll
venclexta first far drug reach market shown
remark efficaci cll notabl deliv deep respons minim
residu diseas neg mani patient venclexta approv april
cll becom part standard care diseas
drug develop collabor roch leader haematolog
cancer thank rituxan gazyva compani share develop cost
consolid sale pay roch profit share us sale royalti
roch test venclexta first-lin cll set phase
trial could open signific proport first-lin patient co-
exist medic condit also explor combin venclexta
imbruvica extrem promis earli data refractori cll set
combin deliv impress data could becom potent chemotherapy-fre
option patient
addit cll drug shown impress earli data aml specif
patient inelig induct chemotherapi encourag data relaps
refractori multipl myeloma patient expect venclexta expand
popul come year
forecast venclexta sale potenti us alon two-
third sale come cll appli risk adjust unapprov indic
fall us global sale trajectori significantli
ahead consensu
venclexta first approv fda
april treatment
relapsed/refractori cll patient chromosom abnorm call delet
repres around relapsed/refractori cll patient recent gain
approv second-lin therapi cll patient combin rituxan
imbruvica aim expand label venclexta rang
haematolog cancer see tabl includ aml multipl myeloma mm mcl
follicular lymphoma fl dlbcl
although venclexta discov compani chose co-develop
roch global leader haematolog cancer venclexta jointli commercialis
genentech us outsid us consolid
sale pay profit share roch us sale royalti ex-u sale
venclexta fda approv timelin actual expect indic therapi stage
major potenti indic venclexta dlbcl common cll
second common diseas
estim incid target indic us
cancer cell surviv
healthi cell becom damag express pro-apoptot activ bim
kick start process apoptosi program cell death process
function cancer cell abl evad self destruct switch anti-
apoptot protein bind pro-apoptot protein therefor
prevent process take place
make inhibit interest target cancer therapi sever
compani look develop inhibitor displac bim restor
signal system tell cell self destruct mean cancer cell abl
avoid process surviv
venclexta mechan action apoptosi
led way sever first gener inhibitor
drug show promis anti-canc effect also
inhibit bcl-xl close member bcl famili result signific reduct
platelet thrombocytopenia develop next-gener inhibitor
fold greater affin bcl-xl drug venetoclax show
remark efficaci cll approv brand name venclexta
venclexta cll move toward
venclexta cll
venclexta cll
venclexta cll
venclexta first approv came treatment cll patient specif
genet abnorm delet recent venclexta label expand
includ cll patient receiv least one prior therapi base excel
result murano trial
murano investig venetoclax combin rituximab r/r cll
venetoclax combin show clear superior standard chemo-immunotherapi
regimen bendamustin rituximab patient surviv two year
without diseas progress compar receiv bendamustin
term investigator-assess hazard ratio impress
median still reach venclexta/rituxan arm
one impress featur murano trial larg percentag
patient abl obtain deep respons best outcom minimum
residu diseas neg achiev patient good degre durabl
murano durabl respons venclexta plu rituxan
next major cll trial read phase studi importantli
first-lin trial test combin venclexta gazyva versu chlorambucil
gazyva accord clinicaltri gov data primari end-point read
late although may hear compani earli
success would expect phase trial initi explor
potenti first-lin regimen eg venclexta imbruvica venclexta
discuss venclexta role cll number expert field
feedback robust support widespread adopt product new
data emerg insight includ follow
tumour lysi syndrom tl big issu earli studi patient bulki
diseas fast aggress destruct cancer cell caus venclexta result
sever sever case tl result roch develop step wise dose
ramp-up schedul minimis tl risk physician seem feel comfort
approach tl uniqu venclexta specialist cll fulli awar
issu dose ramp adequ monitor success mitig risk
mrd- compel aspect venclexta efficaci seen murano
studi high percentag patient venclexta rituxan achiev minim residu
diseas neg indic virtual complet diseas erad
achiev mrd- associ better surviv outcom notabl imbruvica
reson studi show low rate complet respons investig
patient may need chronic therapi one disadvantag btk inhibitor eg
imbruvica lack deep respons observ fast rebound diseas
withdrawn result patient need stay btk inhibitor
long term time key toxic risk atrial fibril bleed accumul
hand venclexta appear drive deep respons patient
come therapi two year murano trial design
venclexta well toler physician tell us venclexta well toler
patient dose ramp use avoid tl beyond risk neutropenia
typic straightforward manag issu tend low grade eg
summari cll mainstay indic venclexta deliv excel
data relaps refractori set murano
strong data intens
venclexta aml strong data
venclexta aml
strong data
venclexta aml
venclexta aml
strong data
earli data aml set shown encourag efficaci venclexta
first-lin therapi choic intens chemotherapi anthracyclin cytarabin
deliv high rate clinic remiss howev gener older
popul around patient deem frail toler intens chemo
updat data present phase ib studi older patient
inelig intens chemotherapi venclexta administ azacitidin
decitabin combin venclexta deliv mani complet respons
longer overal surviv histor data chemo alon suggest
updat result
fda grant breakthrough design base phase ib data
acceler file expect year confirmatori phase trial way
investig venclexta plu cytarabin venclexta plu azacitidin aml data
expect late therefor envisag scenario
venetoclax routin ad treatment alongsid current standard care
perhap import sub -- -- popul target
yeloma perhap import sub
venclexta mmmmultipl
venclexta
popul target
perhap import sub
venclexta
venclexta
perhap import sub
popul target
popul target
treatment multipl myeloma transform recent year thank advent
proteasom inhibitor pi immunomodulatori drug imid target antibodi
eg howev patient benefit extend overal surviv
drug provid
sever genet abnorm identifi malign plasma cell
patient highest risk diseas progress one chromosom transloc
call found around multipl myeloma patient hallmark
mutat myeloma cell overexpress rel bcl-xl mcl-
thu appear key anti-apoptot driver cancer cell
last year data publish phase trial monotherapi venclexta
patient highli refractori diseas median five prior therapi all-com
object respons rate encourag patient analys
statu clear activ mainli deleteri transloc
venclexta monotherapi refractori multipl myeloma activ patient
note pr partial respons vgpr good partial respons cr complet respons scr stringent complet
addit anoth phase ib trial publish similar time investig venclexta
combin bortezomib dexamethason relapsed/refractori multipl
myeloma patient receiv median three prior therapi trial
patient receiv venclexta combin proteasom inhibitor velcad
venclexta bortezomib/dexamethason refractori multipl myeloma impress activ
prior
note pr partial respons vgpr good partial respons cr complet respons scr stringent complet
trial venclexta data look compar darzalex combin
better although trial rather small
combin bortezomib
dexamethason relapsed/refractori multipl myeloma due complet septemb
mean could approv second-lin set end
interestingli also current test venclexta combin darzalex
phase ii trial due complet novemb success could rapidli boost
use venclexta multipl myeloma
believ good chanc venclexta find import role multipl
myeloma even limit refractori patient high risk transloc
could still equat relapsed/refractori patient
summari robust data three indic cll aml multipl myeloma
area underpin major forecast
venetoclax versu standard care
r/r cll del
r/r cll del
venetoclax azacitidin decitabin
data indic stand yet
data indic
stand yet
stand yet
data indic
data indic
stand yet
roch present earli data cell cancer
find data excit seen cll aml mm
although dlbcl present larg estim popul size efficaci data
overwhelmingli posit far phase studi investig venclexta monotherapi
patient r/r non-hodgkin lymphoma nhl produc orr delay
progress one month dlbcl notori aggress type nhl treat
relapsed/refractori diseas difficult efficaci may prove better first-lin set
howev still signific risk trial space disappoint
r/r follicular lymphoma fl interim result phase ii studi look venclexta
combin bendamustin rituximab br produc overal respons rate
versu br alon although monotherapi data look better dlbcl
limit addit benefit combin therapi view larg
revenu opportun drug
monotherapi r/r mcl venclexta perform well overal respons rate
month phase trial combin ibrutinib due read
march howev even combin success unlik drive
larg revenu growth due small popul size
venetoclax monotherapi r/r nhl
although forecast potenti futur sale indic market share
assumpt low sale heavili risk-adjust
product us alon although risk
ssumption aaaa product us alon
product us alon
product us alon
built detail us model venclexta cover indic discuss
assum venclexta wac cost per day dose discount
net sale number sinc approv price venclexta risen pa assum
modest price increas none thereaft
key assumpt indic tabl
venclexta market assumpt indic us
forecast us risk-adjust sale grow around expect cll
remain cornerston sale nearli two-third project revenu come
indic
differ consensu
differ consensu
differ consensu
differ consensu
believ venclexta signific potenti strategi present
suggest nomin global sale could approach
sale forecast imbruvica venclexta
less optimist global sale howev major
risk-adjust non-hodgkin lymphoma indic could certainli
drive upsid nevertheless sale trajectori significantli ahead consensu
consensu expect sale wherea level
risks/wher could wrong
risks/wher could wrong
risks/wher could wrong
risks/wher could wrong
perhap biggest area uncertainti venclexta forecast model
opportun indic mcl dlbcl fl limit clinic data
indic far result assum low market share
signific risk multipli
howev potenti larg indic exampl gain share
dlbcl risk weight could add least peak sale pivot data
major diseas area expect around could result venclexta
forecast revis upward
elagolix novel oral therapi late-stag develop treatment
endometriosi uterin fibroid two indic signific unmet need
view endometriosi commercially-relev indic
forecast peak sale us alon
risankizumab third market monoclon antibodi lead indic
psoriasi behind competitor time ahead dose profil
addit payer/physician relationship drive uptak
cautiou guidanc inflammatori bowel diseas opportun
forecast peak global sale
upadacitinib third jak inhibitor market jak inhibitor combin
potent efficaci biolog conveni oral pill howev
rel dirti class safeti standpoint led signific regulatori
hurdl dichotomi price strategi abbvi molecul strong data
lead rheumatoid arthriti indic addit evid efficaci atop
dermat crohn diseas forecast peak global sale
elagolix endometriosi uterin fibroid
elagolix gonadotrophin releas hormon gnrh antagonist develop
endometriosi uterin fibroid endometriosi lead indic
commerci relev view
phase data strong drug test two dose top
dose appear resembl gnrh agon drive complet estrogen suppress
effect caus vasomotor symptom loss bone miner densiti
like prevent long-term use
lower dose lower efficaci better toler may offer chronic
treatment option combin regular bone scan although also test
add back hormon therapi way mitig vasomotor side-effect
file us approv late receiv prioriti review pdufa
date year howev seemingli prompt safeti concern richter
esmya fda request time review liver function data
delay pdufa three month year
endometriosi common debilit condit affect pre-
menopaus women us assum one-third suffer treat next-
gener agent elagolix captur third market could expect peak
sale us alon
endometriosi common poorli treat condit
common poorli treat condit
common poorli treat condit
common poorli treat condit
endometriosi occur endometri tissu womb line inadvert pass
fallopian tube periton caviti tissu adher extern surfac
ovari uteru tissu establish blood suppli nerv access
tissu retain hormon sensit grow becom inflam
condit remark common women reproduct age suffer
endometriosi degre endometriosi often lead signific pelvic pain
pain period dysmenorrhea caus infertil
main driver problemat ectop endometri tissu estrogen thu primari
treatment aim suppress estrogen product activ
first-lin therapi typic nonsteroid anti-inflammatori nsaid pain relief
progestin contain oral contracept suppress hormon releas fsh follicl
stimul hormon lh luteinis hormon anterior pituitari
approach adequ control symptom second-lin therapi reli
gonadotropin-releas hormon gnrh agonist like abbvi lupron depot gnrh
releas hypothalamu puls promot hormon product
pituitari constant activ
receptor
downregul gnrh signal revers shut
gnrh agonist
mode action gnrh agonist mean take sever week work
chronic gnrh activ downregul receptor take time earli phase
gnrh agonist activ actual exacerb endometriosi symptom
addit profound estrogen suppress effect gnrh agonist similar
menopaus often associ hot flush loss bone miner densiti
result gnrh agonist limit six month use time unless supplement
elagolix potenti gnrh antagon
potenti gnrh antagon
potenti gnrh antagon
potenti gnrh antagon
elagolix oral direct gnrh antagonist sever theoret advantag gnrh
agonist gnrh agonist slow onset risk hormon flare gnrh
antagonist work fast flare addit gnrh agonist lead full estrogen
suppress link drawback bone miner densiti wherea variabl dose
gnrh antagonist allow control degre estrogen suppress thu
potenti lessen neg effect bone densiti blood lipid
complet two phase trial elagolix elari endometriosi ii em-
em-ii data publish new england journal medicin
trial six month durat clearli show good efficaci reduc
endometriosi associ pain howev particularli higher dose test side-effect
notabl includ signific loss bone miner densiti current limit
durat use gnrh agonist
pt reduc dysmenorrhea decreas
stabl use analges
pt reduc nonmenstru pelvic pain
decreas stabl use analges
lipid chang month
lipid chang month
lipid chang month
lipid chang month
percent chang ldl-c
percent chang hdl-c
percent chang ldl-hdl ratio
bone miner densiti chang month
bone miner densiti chang month
bone miner densiti chang month
bone miner densiti chang month
dose test once-daili elagolix deliv partial estrogen
suppress wherea twice-daili drug deliv near complet estrogen
suppress akin chronic gnrh agonist activ
clear dose respons relationship bid twice day give markedli
better improv menstrual pain dysmenorrhea non-menstru pain
qd day dose dose markedli better placebo
elagolix estrogen suppress lead significantli higher incid hot
flush headach similar gnrh agon although qd dose
clearli better toler bid dose
like gnrh agon unfavour lipid chang observ particularli
high dose
addit high dose also show mark deterior bone miner densiti
close level observ gnrh agonist given issu restrict
gnrh agonist use six month would expect appli high dose elagolix
trial elagolix effect gener deliv accept safeti profil
howev high dose safeti profil seem compar seen gnrh
agon restrict use six-month cours key elagolix success
whether fda consid longer treatment durat lower dose
whether lower efficaci dose level suffici win substanti usag
term follow -- --
add back longongongong -- -- term follow
add back
keykeykeykey
add back
add back
abbvi pivot endometriosi studi test elagolix monotherapi without add
back low dose estradiol progestin counteract bone miner densiti loss
hot flash howev run follow-up studi test add back therapi
trial read proven effect add back could
key chronic dose elagolix
addit long-term safeti perspect data
extens studi elari em ii could support long-term use
like key question regulatori review
anoth issu physician perspect elari trial conduct
placebo thu hard judg much effect elagolix potenti
cheaper option combin contracept pill
elagolix file us fda need time review
elagolix file us fda need
time review
elagolix file us fda need
elagolix file us fda need
time review
time review
success complet elaris-em phase programm file
elagolix approv us fda grant prioriti review elagolix
base strength data set pdufa date
april fda inform need extend time review addit data
nda pdufa date extend three month specif
fda request time examin addit data involv liver function test
trial note liver function data mention new england journal
medicin public elari trial associ supplementari appendix
mean hard judg whether repres seriou regulatori issu
compani develop new agent endometriosi two
agent phase ii develop encourag earli data
takeda/myov relugolix potent gnrh antagonist similar mechan
elagolix two major phase trial endometriosi spirit unlik
myovant studi relugolix combin add back therapi
bayer select progesteron receptor modul sprm vilaprisan shown
good phase ii data uterin fibroid phase indic
also phase ii trial endometriosi
myovant claim relugolix potent elagolix achiev complet
suppress gnrh pathway once-daili dose although could abl
match elagolix bid dose would also expect carri vasomotor
bone miner densiti side-effect howev mitig risk relugolix trial
contain parallel add back therapi low-dos estrogen/progestin design mitig
side-effect may allow myovant match efficaci elagolix high-dos
without side-effect limit durat use view relugolix could potent
competitor endometriosi albeit sever year behind elagolix
bayer vilaprisan even behind yet enter phase
endometriosi thu difficult judg profil stage howev phase ii data
uterin fibroid extrem encourag reduct fibroid size
top dose given fibroid like ectop endometri tissu hormone-sensit
vilaprisan similarli suppress effect endometriosi side-effect
profil could also prove differ potenti benign gnrh antagon
howev still earli draw conclus vilaprisan
phase trial elagolix endometriosi
phase trial elagolix uterin fibroid
phase trial relugolix endometriosi uterin fibroid
phase trial vilaprisan uterin fibroid
chang bmd lumbar spine
phase trial uliprist uterin fibroid
model opportun
model opportun
model opportun
model opportun
endometriosi common estim pre menopaus women
suffer condit assum mid-point preval
accord us censu bureau data femal age
live us thu could women live endometriosi
us
level symptom pain burden like vari consider rel mild
sever assum mani women gain adequ pain relief use nsaid
without hormon therapi oral contracept addit women
activ tri get pregnant elig elagolix therapi also note
women evid low bone miner densiti baselin exclud
trial result assum one-third endometriosi suffer would
elig gnrh antagonist therapi
price combin contracept progestin cheap work well mani
women may restrict premium newer agent elagolix relugolix
assum daili cost per day equat six month suppli
dissimilar price recent launch uliprist canada uterin
assum elagolix captur one-third patient popul price point
us sale endometriosi could amount
addit elagolix trial uterin fibroid data expect later year
although assum smaller patient popul base number
hysterectomi conduct year condit nevertheless could add
anoth sale
appli modest risk-adjust probabl approv given advanc
stage regulatori progress elagolix
share taken elagolix
share taken elagolix
risankizumab captur late piec larg pie
risankizumab anti antibodi develop psoriasi rang
autoimmun indic drug shown excel combin
efficaci safeti lead dose profil compar psoriasi
howev approv risankizumab third market third wave
psoriasi drug inde estim biolog drug market
therefor despit offer compel therapeut profil expect
risankizumab becom class leader psoriasi addit indic within
inflammatori bowel diseas offer upsid biolog histor enter
market slow pace data date suggest differenti
nevertheless well-establish posit payer physician
provid degre competit advantag support reason penetr
rheumatolog set
forecast peak sale risk weight pre-approv
acquir -- --
acquir
acquir
acquir
risankizumab monoclon antibodi signal cytokin heavili
implic develop inflammatori condit mechan well-
valid tremfya morphosi also target approv last year
moder sever psoriasi
drug origin develop boehring ingelheim bi acquir
commercialis right pay bi development regulatori
mileston addit royalti net sale assum tier
class repres third wave psoriasi target exclud less-
efficaci stelara also target tremfya first market class
reason launch consensu expect sale sun pharma
ilumya approv us may like launch come
month drug therefor third market third-wav class howev
risankizumab partli differenti dose efficaci
timelin drug class launch psoriasi
along upadacitinib risankizumab complet abbvi strategi bring new wave
anti-inflammatori asset market humira contribut top line wane
abbvi janu kinas jak inhibitor collect
develop seven indic three overlap risankizumab first indic
psoriasi indic follow
efficaci safeti data screen favour
efficaci safeti data screen favour
efficaci safeti data screen favour
efficaci safeti data screen favour
phase data three risankizumab studi replic studi
stelara activ compar immvent humira activ compar
full data set yet publish key efficaci end-point upper
end competitor safeti data also encourag new signal emerg
phase programm imbal seriou advers event
note despit favour safeti statist minor cardiovascular cv
signal one patient die sudden cardiac arrest day last
dose studi drug anoth die day last dose caus death
unknown although patient past histori cv risk factor immvent
patient die acut myocardi infarct day trial patient
risankizumab psoriasi phase efficaci data head head
week
week
week
week
psoriasi biolog compar efficaci head head
dose confer advantag competitor
dose confer advantag competitor
dose confer advantag competitor
dose confer advantag competitor
consid efficaci safeti data view tremfya cosentyx taltz main
competitor risankizumab drug offer dose benefit three
psoriasi biolog week dose
combin quarterli dose high efficaci lack seriou safeti concern
result highli competit profil
nb rel safeti concern defin presenc absenc black box warn
indic outsid psoriasi
indic outsid psoriasi
indic outsid psoriasi
indic outsid psoriasi
keep abbvi humira strategi risankizumab late-stag develop
three indic outsid psoriasi repres signific growth
opportun right
pathogenesi overlap psoriasi strong psoriasi
also suffer tendon insert inflamm enthes joint stiff pain
long term lead perman disabl
major drug approv psoriasi also label expect
differ inde two alreadi convinc phase ii efficaci data tremfya
achiev respons patient risankizumab achiev mean
respons patient data par phase result
taltz cosentyx risankizumab current singl phase trial
due complet august plan launch indic
ibd umbrella term encompass crohn diseas cd ulcer coliti
uc ibd grow biolog market signific unmet need current biolog
respons durabl associ high discontinu rate
uc characteris sever inflamm colon mucosa caus varieti
gastrointestin gi system side effect patient suffer diarrhoea gi bleed
weight loss fatigu fever
patient mild diseas well-control steroid sever
diseas progress despit short steroid cours requir intens medic
therapi peak medic potenti uc cap howev fact diseas
effect cure surgic remov colon inde patient
experi sever clinic cours nearli third cohort undergo colectomi
biolog therapi reserv second-/third-lin treatment current consist
anti-tnf therapi typic remicad sever patient entyvio
moder end spectrum drug entrench standard care
risankizumab current phase ii dose-seek studi uc progress
phase placebo-control trial due complet note jak inhibitor
expect enter therapi area soon follow recent posit advisori
committe meet pfizer xeljanz physician feedback xeljanz posit
drug rapid action could use relaps induct bridg switch safer
cd anoth inflammatori disord gi tract patholog differ uc
two main way first affect entir gi tract colon second
inflammatori process penetr muscl layer caus fistula associ
downstream effect unlik uc cd surgic cure
medic treatment moder sever cd take top-down approach biolog often
use first-lin combin tradit diseas modifi agent uc anti-
tnf most-establish class roughli third patient treat anti-tnf
therapi show primari respons anoth third develop secondari failur
intoler treatment cd thu repres signific unmet medic need
interestingli unlik psoriasi drug actual trigger worsen cd contrast
agent target axi appear work well inde js stelara
first approv cd septemb compel efficaci data take share
tysabri adhes molecul inhibitor also approv cd rare use
absenc concurr multipl sclerosi due risk progress multifoc
remiss rate seen placebo caveat cross-trial comparison
data compar favour anti-tnf appear least strong
seen stelara differ patient popul prior tnf exposur follow-up
time period make earli comparison especi difficult risankizumab appear
safe effect cd put ahead line stelara
although complet phase data set expect
risankizumab phase ii crohn remiss rate
stelara phase crohn remiss rate
risankizumab potenti ibd limit
risankizumab potenti ibd limit
risankizumab potenti ibd limit
risankizumab potenti ibd limit
 expect ibd major biolog growth area next decad
inde biolog penetr low us row mani patient sub-
optim treat compani expect market grow higher biolog
penetr greater number approv drug
opportun clear seen data date suggest
risankizumab provid differenti option ibd patient ignor cross-trial
comparison stelara compar efficaci cd unlik psoriasi efficaci uplift
yet appar time risankizumab approv cd stelara
approv indic five year
limit risankizumab potenti novel oral agent also enter space
particularli target jak pathway physician feedback suggest
risankizumab stand chanc claim share ibd like limit
absenc overwhelmingli compel efficaci safeti data
note phase ii data risankizumab cd follow iv infus
week phase dose yet disclos studi
subcutan intraven form equival efficaci data subcutan
form could shift balanc favour
model opportun
model opportun
model opportun
model opportun
hous psoriasi model calibr chang inter- intra-class
dynam anti-tnf therapi base current preval
figur physician feedback estim address us psoriasis/psoriat
arthriti market patient
peak assum split anti-tnf within
includ stelara assum tremfya risankizumab take
share tremfya take slight major due first-mov
today wac price discount assumpt point global
risankizumab sale psoriasi psoriat arthriti account
modest increas net realis price per year forecast sale rise
indic alon
discuss share confid ibd potenti
assum modest sale uc cd combin
result peak forecast guidanc larg due bearish
view ibd potenti convinc differenti data
indic would caus us revisit forecast
upadacitinib third entrant larg market
upadacitinib oral jak inhibitor launch
inhibitor repres
rheumatoid arthriti provid once-daili oral pill conveni typic small
molecul drug potent efficaci biolog
latest gener anti-inflammatori drug
howev jak blockad rel dirti mechan numer off-target
effect safeti concern result arduou regulatori process pfizer
xeljanz lilli olumi
abbvi jak inhibitor like third market benefit increas
physician familiar class whole phase toxic data especi key
approv prescrib adopt notabl rate venou thromboembol
vte upadacitinib pivot trial programm look similar low dose
olumi gain approv thu expect close scrutini data
ultim expect approv
forecast global sale ra appli risk weight
captur regulatori risk given vte signal
also test upadacitinib rang autoimmun indic
encourag data area atop dermat howev jak inhibitor
also explor area includ next-gener high specif jak
inhibitor data upadacitinib field read
forecast peak sale non-ra indic risk-adjust given
earlier stage develop
total see un-risk-weight peak sale upadacitinib model risk-
adjust peak sale
jak includ intracellular immun signal transduc
respond specif signal differ downstream effect although
signific overlap exist two approv drug class aim autoimmun
xeljanz tofacitinib first-in-class oral jak inhibitor first launch
drug tumultu start two initi refus european medicin
agenc initi disappoint launch period due concern seriou infect
malign gastrointestin perfor
howev xeljanz approv us eu one fastest-grow non-
tnf drug us second-lin ra care note franchis benefit
introduct xeljanz xr conveni once-daili pill patient favour drug
conveni efficaci speed onset tradit tnf inhibitor take month
effect wherea xeljanz act within week
olumi baricitinib eli lilli second jak inhibitor eventu reach us
market june initi reject fda april due incomplet
data packag clotting-rel safeti concern drug approv europ
japan label specifi caution patient risk factor deep vein
thrombosi dvt pulmonari embol pe us low dose avail
claim superior humira drug black box warn
malign seriou infect thrombosi
upadacitinib efficaci ra far good
upadacitinib efficaci ra far
good
upadacitinib efficaci ra far
upadacitinib efficaci ra far
good
good
upadacitinib track regulatori submiss ra also studi
psoriat arthriti ankylos spondylarthropathi atop dermat cd uc
efficaci standpoint molecul stand well xeljanz
olumi compar efficaci result compound attempt
select trial similar durat treatment arm patient cohort follow
upadacitinib phase studi select-next upadacitinib versu
placebo patient adequ respond convent system dmard
dose includ
filgotinib phase iib studi darwin filgotinib versu placebo
patient inadequ respons methotrex dose includ
olumi phase studi ra-build olumi versu placebo
patient adequ respond convent system dmard dose
includ
xeljanz phase iib studi xeljanz humira versu placebo patient
inadequ respons dmard data week larg xeljanz
trial either wrong durat studi monotherapi recommend
dose includ
compar american colleg rheumatolog acr score
standardis measur ra diseas respons therapi look gap
placebo activ agent rather absolut acr attain
eu
comparison perfect standardis comparison
reduc confound possibl one major caveat trial durat six-
month comparison would prefer compar phase data
abbvi drug week bound measur
howev durabl data upadacitinib patient stabl dose
convent system dmard inadequ respons intoler
biolog dmard select-beyond trial confirm upadacitinib efficaci last
least week arm broadli par higher dose time
similarli result final phase develop trial ra select-earli
show durabl respons week clear superior methotrex
methotrex nave patient upadacitinib dose could give
jak specif key cleaner profil
specif key cleaner profil
specif key cleaner profil
specif key cleaner profil
jak inhibitor plagu safeti issu like due divers
array downstream effect jak inhibit member jak signal group
primari signal role although overlap
specif pro-inflammatori action play role tnf
contrast crucial haematopoiesi ie product blood cell
jak mediat immun system genet defici signal caus sever
clearli specif appropri target anti-inflammatori drug upadacitinib
thought although laboratori measur specif
alway correl clinic toxic inde data suggest jak inhibit
vari accord dose pharmacokinet variabl
within class follow concern rais late-stag data
xeljanz black box warn seriou infect malign
addit warn gi perfor drug label note patient
take xeljanz seven control clinic studi develop malign
patient took placebo none develop cancer
olumi ema label advis caution infect certain haematolog
abnorm expect anti-inflammatori drug uniqu
olimi caution rise blood lipid potenti clot risk
fda felt imbal thromboembol event placebo-control trial
high justifi approv first instanc although reassess drug
approv lower dose black box warn seriou infect malign
thrombosi
thrombot risk like dictat success
alongsid result select earli trial also releas collat venou
thromboembol vte data across entir select programm shown
face patient either dose upadacitinib lower vte rate
humira control period vte incid upadacitinib appear
similar placebo/methotrex group
exposure-adjust adjud vte incid rate select trial
nb incid defin patient per year exposur
data appear favour clear incid rate adjust
exposur data adjud know absolut
placebo rate group data methotrex without
breakdown difficult determin degre upadacitinib increas vte risk
expect data close scrutinis fda given regul concern
olumi exposure-adjust vte rate per patient year
low dose per patient year high dose slightli higher
data upadacitinib upadacitinib appear minor mace signal
could also caus rais thrombot profil balanc given olumi
gain approv think highli like upadacitinib although cleaner
safeti label compar olumi mean guarante
product far behind
far behind
far behind
far behind
filgotinib galapagos/gilead purport highli select inhibitor phase ii
data darwin trial show patient receiv highest dose
filgotinib daili monotherapi achiev
respons respect note result non-signific
dose middl dose respons latest interim result
open-label extens trial darwin appear demonstr consist efficaci
safeti paramet filgotinib select translat reduc real world
toxic could seriou competitor upadacitinib phase data expect later
year
jjjjak trade
ak trade
ak trade
ak trade
mention near-term opportun upadacitinib ra drug
develop five indic
five indic think atop dermat ad could prove
interest recent publish top-lin phase iib data upadacitinib patient
moder sever ad inadequ control topic treatment efficaci
data impress compar dupix rapidli becom gold
standard compar underserv patient pool
upadacitinib dupix versu placebo week
upadacitinib dupix versu placebo week
judg data high dose upadacitinib superior dupix regard
clinic efficaci usual caveat trial compar howev
toxic profil drug close monitor report new safeti
signal detect importantli malign thromboembol event
occur ad patient popul typic younger less at-risk dvt/pe
ra longer larger trial requir better establish toxic profil
januari upadacitinib grant breakthrough therapi design fda
use atop dermat plan start phase trial soon potenti gain
approv although current trial list clinicaltri gov
compani expect gener annual sale indic
howev two jak inhibitor also late-stag develop atop dermat
phase ii olumi fail improv upon placebo show posit
differ low dose given drug extens safeti concern lack
compel efficaci data stage suspect olumi fail gain traction
indic
pfizer select inhibitor could greater import phase ii
data strong week patient receiv averag reduct
easi score compar placebo compar upadacitinib pfizer
drug alreadi fda breakthrough therapi design use atop dermat
current phase trial due complet
upadacitinib reduct easi score
upadacitinib reduct easi score versu placebo
averag reduct easi score
upadacitinib also demonstr strong efficaci phase ii trial cd support
advanc phase believ drug could deliv sale
use cd alon make third-largest potenti revenu opportun
behind use rheumatoid arthriti atop dermat first three phase trial
cd due read expect gain approv
upadacitinib galapagos/gilead filgotinib current two jak inhibitor
late-stag develop indic difficult compar phase ii data
two jak inhibitor current avail treatment option ie stelara entyvio due
signific differ trial design underli patient popul howev
earli set earli upadacitinib appear superior improv
achiev remiss compar current standard care wherea filgotinib appear line
upadacitinib toxic profil indic howev far benign clear
dose-rel risk advers event highest dose show case skin cancer gi
perfor myocardi infarct phase dose yet disclos
trial readout upadacitinib filgotinib cd
moder sever cd fail anti-tnf therapi
moder sever cd
moder sever cd anti-tnf non-responder/intoler
also develop two jak inhibitor use cd jak
inhibitor jak kinas inhibitor phase ii trial investig
agent due complet februari
also investig efficaci upadacitinib three indic detail
data compar rel efficaci
indic expect upadacitinib
characteris back pain
progres spinal stiff
associ psoriasi
characteris recur
episod inflamm
mucos layer colon
order model opportun ra make follow assumpt
moderate-to-sever ra popul well-control tradit
dmard us kol feedback assum major non-dmard patient take
anti-tnf
within non-dmard non-tnf popul patient forecast steadi
ramp-up jak inhibitor penetr
xeljanz six-year head start time jak enter market
assum retain major market share jak inhibitor roughli equal split
filgotinib upadacitinib minor olumi
olumi launch signific label disadvantag compar xeljanz lilli
price accordingli half list price balanc think launch
price pariti xeljanz given clinic data although concess price would
downsid forecast
result global sale upadacitinib risk-adjust
reflect degre regulatori risk
label broaden indic psoriat arthriti atop dermat
ankylos spondyl inflammatori bowel diseas would add signific upsid
ra forecast although sever year phase data indic
addit note xeljanz receiv complet respons letter
psoriat arthriti success ra necessarili translat indic
nevertheless believ
upadacitinib sale potenti atop dermat crohn diseas two
note broadli agre assess ra opportun
forecast nomin un-risk-adjust sale close aspir
remain indic believ nomin sale potenti
howev trial still need read set expect timelin data
launch laid
pivot trial timelin upadacitinib indic
stage develop
stage develop
stage develop
stage develop
compar jak question mark
phase data superior dupix possili inferior
second-gener jak
data anti-tnf intolerant/non-respond
popul promis difficult determin
superior due differ trial design
adjust sale addit indic
bn risk -- -- adjust sale
assum risk
adjust sale
bn risk
bn risk
adjust sale
five indic avail upadacitinib compani produc
promis data two atop dermat cd togeth repres addit
peak sale estim risk weight forecast standard
phase success rate reflect possibl competit jak inhibitor
clinic risk pivot trial read strongli anticip
total therefor model total peak global sale consist risk-
adjust ra risk-adjust indic
forecast versu consensu upside/downsid
forecast sit close consensu upadacitinib although forecast
significantli nomin sale aspir
main sourc upsid would clearli strong data non-ra indic
particularli atop dermat inflammatori bowel disord
downsid think two potenti sourc disappoint first weak
data non-ra indic could lower peak sale expect around
second lilli took bold step launch jak inhibitor olumi steep discount
competit reflect weaker label versu expect think
price win efficaci see tanzeum market howev need watch
olumi launch close turn market price count
efficaci would serious neg consequ compani aim
prosper jak inhibitor
final reckon futur secur price
abbvi intern extern effort rebuild portfolio result
impress line-up growth driver medium term expect sale
eight product add top line
howev must view alongsid outlook success
product humira set face biosimilar competit europ year humira
close peak sale us biosimilar competit like onward
like see fast eros franchis
result much growth new product off-set sale
fall back toward level forecast
thu tale two timefram compani deliv strong sale
earn growth forecast five-year compound-annual-growth-rate sale
oper profit howev beyond expect sale earn move
declin could multi-year period unless new product flow
significantli surpris upsid
trade non-gaap ep forecast repres
discount broader us larg cap sector discount widen
come year ep growth outpac us peer estim
price-to-earnings would discount us peer howev earn highli like
move declin beyond discount warrant
dcf model point fair valu would repres discount
us peer group peak non-gaap ep initi hold
recommend price target
eve humira like loss exclus us recent
pend drug launch gener sale accord forecast
underpin sale growth pa close
highest larg cap sector
humira must fall
howev even strong new product growth humira brink
biosimilar eros us still repres sale
forecast sale switch declin annual eros rate pa
could clearli mitig posit product flow
pipelin in-licens activ risk-adjust base case sale line
move declin
margin may vulner
guid non-gaap ebit margin climb toward
assum compani broadli reach target
busi close highest ebit margin sector gilead top
today thank concentr special portfolio believ margin prove
unsustain humira eros us intensifi result think post-
sale declin amplifi swifter earn declin margin retreat
peak closer margin structur
sale ebit index
sale ebit index
sale ebit index
sale ebit index
multipl market pay earn
forecast non-gaap ep peak point like declin roch may
indic market valu compani face consider eros
compani also face scenario pharmaceut sale
challeng biosimilar competit horizon howev one critic
differ roch eros expect stagger eu us
biosimilar entrant differ timepoint across three product differ loss
exclus timefram humira situat stark biosimilar competit one
drug one geographi us put sale pressur immedi
think seriou challeng avoid earn revers declin
beyond think multipl warrant assum share de-rat
stock price still go around year time
includ averag dividend yield could result total annualis sharehold
return mid- high singl digit view suffici attract
dcf model base cash flow project assumpt includ
use cash flow primarili pay debt
cost equiti cost debt
termin growth
model suggest fair valu per share
share issu end
conting consider risankizumab
net debt end prior year
initi hold rate price target
assembl impress collect new product signific sale
potenti forecast main growth driver fall significantli short
abbvi nomin sale aspir agre imbruvica venclexta risankizumab
upadacitinib hold multi billion dollar sale potenti
could clinic data close gap
could clinic data close gap
could clinic data close gap
could clinic data close gap
us sale key upsid would success pancreat
cancer current heavili risk-adjust forecast
forecast mainli driven cll aml
publish data strong success dlbcl fl would
open signific upsid
compel data ibd would rais risk-weight
strong phase data atop dermat could open
disappoint data triniti although done sick
patient lead probabl success
strateg updat berenberg analysi
forecast key growth driver ad impress sale
howev need view alongsid declin humira like result
sale move declin beyond
product sold
royalti profit split
sell gener administr
 sale
research develop
 sale
total oper cost expens
earn incom tax expens
equival
account receiv net
prepaid expens
properti equip net
intang asset net amort
current portion long-term debt leas
account payabl accru liabil
long-term debt leas oblig
net parent compani invest abbvi
common stock held treasuri cost
accumul comprehens loss
total liabil equiti
total liabil equiti
total liabil equiti
total liabil equiti
flow oper activ
flow oper activ
flow oper activ
flow oper activ
amort intang asset
chang fair valu conting consider
acquir in-process research develop
devalu loss relat venezuela
account receiv
prepaid expens asset
account payabl liabil
flow oper activ
flow oper activ
flow oper activ
flow oper activ
flow invest activ
flow invest activ
flow invest activ
flow invest activ
acquisit invest net cash
acquisit invest
acquisit pharmacycl inc net cash
acquisit properti equip
releas restrict fund
releas restrict fund
releas restrict fund
releas restrict fund
purchas invest secur
sale matur invest secur
flow invest activ
flow invest activ
flow invest activ
flow invest activ
flow financ activ
flow financ activ
flow financ activ
flow financ activ
net chang short-term borrow
proce issuanc long-term debt
repay long-term debt capit leas
purchas treasuri stock
proce exercis stock option
net transact exclud non-cash item
flow financ activ
flow financ activ
flow financ activ
flow financ activ
effect exchang rate chang cash
net increas cash equival
net increas cash equival
net increas cash equival
net increas cash equival
equival begin period
equival end period
equival end period
equival end period
equival end period
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener invest
pleas note use research report subject condit restrict set forth gener inv
pleas note use research report subject condit restrict set forth gener inv
disclosur legal disclaim end document
